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Active GSK3β and an intact 
β-catenin TCF complex are essential 
for the differentiation of human 
myogenic progenitor cells
C. C. Agley1,4, F. C. Lewis1,2, O. Jaka1, N. R. Lazarus1, C. Velloso1, P. Francis-West3,  
G. M. Ellison-Hughes1,2 & S. D. R. Harridge1,2
Wnt-β-catenin signalling is essential for skeletal muscle myogenesis during development, but its role 
in adult human skeletal muscle remains unknown. Here we have used human primary CD56Pos satellite 
cell-derived myogenic progenitors obtained from healthy individuals to study the role of Wnt-β-catenin 
signalling in myogenic differentiation. We show that dephosphorylated β-catenin (active-β-catenin), 
the central effector of the canonical Wnt cascade, is strongly upregulated at the onset of differentiation 
and undergoes nuclear translocation as differentiation progresses. To establish the role of Wnt 
signalling in regulating the differentiation process we manipulated key nodes of this pathway through a 
series of β-catenin gain-of-function (GSK3 inhibition and β-catenin overexpression) or loss-of-function 
experiments (dominant negative TCF4). Our data showed that manipulation of these critical pathway 
components led to varying degrees of disruption to the normal differentiation phenotype indicating the 
importance of Wnt signalling in regulating this process. We reveal an independent necessity for active-
β-catenin in the fusion and differentiation of human myogenic progenitors and that dominant negative 
inhibition of TCF4 prevents differentiation completely. Together these data add new mechanistic 
insights into both Wnt signalling and adult human myogenic progenitor differentiation.
Canonical Wnt signalling acting via the transcriptional co-activator β-catenin, is known to be critical for skeletal 
muscle myogenesis during embryonic development1–3. In the absence of Wnt ligands, a cytoplasmic ‘destruction 
complex’ maintains the cellular pool of β-catenin at a low level. A key action of this complex is to immobilise 
β-catenin providing glycogen synthase kinase 3β (GSK3β) the opportunity to phosphorylate it on key N-terminal 
serine and threonine residues, thereby marking β-catenin for degradation via the ubiquitin-proteasome pathway. 
Conversely, when Wnt ligands are present, this complex is inhibited and β-catenin remains in its active, unphos-
phorylated, form, which can translocate to the nucleus and regulate Wnt responsive genes via its partnership with 
TCF/LEF transcription factors4.
Little is known about the role of β-catenin in adult skeletal muscle, where it is assumed that many aspects of 
muscle development are recapitulated by the resident progenitor cell population, known as satellite cells, upon 
their activation in response to damage5. In resting muscle, undifferentiated satellite cells exist in a quiescent state 
beneath the basal lamina and directly adjacent to the terminally differentiated syncytial myofibres. In many spe-
cies these dormant satellite cells are most commonly distinguished by their characteristic expression of the paired 
homeobox transcription factor 7 (Pax7); however, unlike in mice, human satellite cells can also be identified by 
their cell surface expression of CD56 (N-CAM)6. When muscle is damaged, satellite cells exit quiescence and 
sequentially express a well characterised cascade of myogenic regulatory factors, which in turn drive the expres-
sion of muscle specific genes. Two of these factors Myf5 and MyoD, are expressed immediately post-activation 
as the cells undergo proliferative expansion as myogenic progenitors, whilst myogenin and myogenic regulatory 
factor (MRF) govern the differentiation of these cells as they work to repair or replace damaged myofibres5,7.
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The overwhelming majority of studies investigating the role of canonical Wnt-β-catenin signalling in skeletal 
muscle have been performed using cultured mouse cell lines. Manipulation of β-catenin levels in these lines has 
been reported to both inhibit8–10 and promote10–15 myogenic differentiation. Studies focusing on primary cells 
from adult mouse muscle and also mature mouse muscle in vivo, indicate roles for Wnt-β-catenin signalling in the 
regulation of both myotube16 and myofibre hypertrophy17. Although Wnt signalling is believed to be conserved 
between species, differences exist in the way satellite cells are identified in mice and humans and there are also 
emerging differences in the behaviour of isolated satellite cell-derived myogenic progenitors18. These differences 
mandate the need for species-specific studies to identify the role of Wnt-β-catenin signalling in human muscle 
adaptation and repair. This is particularly important as dysregulation of Wnt signalling has been implicated in 
sarcopenia, the age-regulated loss of skeletal muscle mass19.
We have investigated the role of canonical Wnt signalling in early passage adult human myogenic progeni-
tors and, in particular, whether it acts as a facilitator or inhibitor of differentiation. Using an immunomagentic 
isolation procedure6,20 in combination with small molecule inhibitors and high-efficiency lentiviral expression 
constructs, we manipulated three key nodes in the Wnt pathway: GSK3, β-catenin, and T cell factor (TCF4/
TCF7L2)21, in bulk populations of purified CD56Pos myogenic progenitors obtained from numerous healthy indi-
viduals at early passage, therefore mitigating the potential impact of extended tissue culture artifacts22.
Manipulation of the core canonical Wnt components we selected disrupted the normal differentiation of 
human myogenic progenitors indicating the importance of this pathway in the regulation of these cells. We found 
that active GSK3 is required for the fusion and differentiation of human myogenic progenitors and that its inhi-
bition represses the normal onset of myogenin expression. We show that while differentiation is not enhanced by 
overexpression of β-catenin, prevention of canonical Wnt signalling during differentiation via disruption of the 
nuclear β-catenin-TCF transcriptional complex completely abolishes differentiation. Together these data show 
that in adult human primary myogenic progenitor cells Wnt signalling is a central regulator of myogenesis and is 
essential for in vitro differentiation.
Results
β-catenin expression in adult human skeletal muscle tissue and primary myogenic progenitors. 
To assess the expression and localisation of β-catenin in adult human muscle, biopsy samples were taken from the 
vastus lateralis and either cryosectioned and analysed using immunohistochemistry, or enzymatically digested 
to allow immunomagnetic enrichment of CD56Pos, satellite cell-derived myogenic progenitor cells (Fig. 1a,b). 
Staining for active-β-catenin (non-phosphorylated)23 on cryosections of human muscle revealed distinct foci 
in many satellite cells, which can be distinguished based upon their location under the basal lamina (Fig. 1c). 
Staining for total-β-catenin was more readily detected in regions of cell-to-cell contact at the periphery of myofi-
bres (Fig. 1d). To examine whether CD56Pos satellite cell-derived human myogenic progenitor cells express 
active-β-catenin upon differentiation, immunomagentically purified primary cultures were established. We 
have previously shown that only cells within the CD56Pos fraction of freshly isolated human muscle and not the 
CD56Neg fraction have inherent myogenic capacity6,20. CD56Pos cells are desminPos and upon serum withdrawal 
readily form myotubes, which express myogenin and myosin heavy chain (MHC)6. In proliferating CD56Pos/
desminPos/Ki67Pos myogenic progenitors, 8–9 days after isolation from human muscle at passage 1, β-catenin 
was detectable only at very low levels in the cytoplasm and there was no clear nuclear accumulation (Fig. 1e). 
Contrastingly, after four days of serum-free culture, which is a stimulus for myogenic differentiation6, these cells 
had terminally differentiated into large branching MHCPos multinucleated myotubes and the expression of cyto-
plasmic and nuclear active-β-catenin increased substantially (Fig. 1f). Together this indicates β-catenin is active 
in the quiescent progenitor cell population, downregulated in proliferating myoblasts and upregulated in differ-
entiating myoblasts suggesting β-catenin signalling acts bi-phasically, either promoting or inhibiting myogenesis 
potentially depending on environmental signals and cell state.
Receptor mediated canonical Wnt pathway activation does not affect myotube formation. 
We sought to activate/inhibit Wnt signalling via the frizzled/LRP co-receptor complex to see if we could manip-
ulate myotube formation. To achieve this, we supplemented the canonical Wnt ligand, Wnt3a, to the growth 
medium of human muscle-derived populations obtained from three separate individuals. As anticipated, west-
ern blotting showed that the addition of soluble Wnt3a induced a significant increase in active-β-catenin levels, 
while total-β-catenin was unchanged (Fig. 2a–c). Wnt stimulated primary cultures also demonstrated a strong 
and reproducible induction of the canonical Wnt target gene AXIN2 within 4 hours of Wnt stimulation, which 
remained elevated for the remaining 16 hour time course (Fig. 2d). These data combined with the detection of 
other pathway components by RT-PCR demonstrate an active and responsive canonical pathway in human myo-
genic progenitors (Figure S1). In addition, when profiling differentiating human myogenic cells against a panel 
of known mammalian Wnt ligands, of the 10 canonical Wnts detected by qRT-PCR, Wnt3a was one of the most 
highly expressed (Fig. S1). To test that Wnt3a was activating β-catenin through its cell surface receptors we added 
Dkk-1, which is known to antagonise Wnt signalling by competing with the LRP receptor24. Addition of Dkk-1 
was able to significantly reduce the Wnt3a-stimulated increase in AXIN2 transcript expression, confirming the 
specificity of Wnt activation (Fig. 2e).
To assess whether receptor mediated stimulation of Wnt signalling would alter the differentiation of freshly 
isolated human myogenic progenitors, primary CD56Pos/desminPos cultures were established and then switched 
to differentiation medium with the addition of Wnt3a at passage 2. After four days in serum-free conditions, both 
control and Wnt3a-treated cultures had differentiated into myotubes; furthermore the myotubes that developed 
in the presence of Wnt3a were visually indistinguishable from control myotubes (Fig. 2f). In both conditions 
myotubes strongly expressed MHC, a marker of terminal myogenic differentiation (Fig. 2f). Immunofluorescent 
quantification revealed that total-β-catenin expression within myotubes and also in undifferentiated mononuclear 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 13189  | DOI:10.1038/s41598-017-10731-1
cells located outside myotubes remained comparable between control and Wnt3a cultures (Fig. 2g,h). Importantly, 
at the doses administered here, myotube area was unaffected by Wnt3a or Dkk-1, despite the ability of these fac-
tors to stimulate and inhibit Wnt signalling, respectively (Fig. 2i). Similarly, immunocytochemistry of Dkk-1 
Figure 1. β-catenin expression in adult human skeletal muscle tissue and primary myogenic progenitors 
(a) Schematic of the experimental procedure whereby muscle tissue was obtained using the Bergström 
needle biopsy technique before being enzymatically digested to release myogenic cells. (b–d) Representative 
micrographs of healthy human muscle cryosections showed (b) CD56Pos satellite cells, scale bar = 20 µm. (c) 
nuclear active-β-catenin expression in many satellite cells and (d) total-β-catenin expression localised at the 
periphery of many myofibers, scale bar = 20 µm. (e) Immunocytochemistry indicated an absence of nuclear 
active-β-catenin in proliferating desminPos/Ki67Pos myogenic cells, scale bar = 100 µm (top), 50 µm (bottom) 
(f) Active-β-catenin was expressed in almost all nuclei of MHCPos multinucleated myotubes following 4 days of 
myogenic differentiation, scale bar = 100 µm. Assays for (b–d) performed on n = 3 biopsies; Staining for (e,f) 
was confirmed on n = 7 biopsies. All staining was performed with technical duplicates.
www.nature.com/scientificreports/
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Figure 2. Receptor mediated canonical Wnt pathway activation does not affect myotube formation. (a) Western 
blot analysis of proliferating human myogenic cells treated with Wnt3a or control (0.3% BSA) for 1, 2, 4, 8 or 
16 h. Equal protein loading was confirmed with β-tubulin immunoblotting and human epidermoid carcinoma 
cells (A431) were used as a positive control. (b) Immunoblot densitometry quantification of active-β-catenin/
tubulin protein expression, *P < 0.05; **P < 0.01; ns: non-significant, (cells derived from n = 3 subjects). (c) 
Immunoblot densitometry quantification of total-β-catenin/tubulin protein expression, (cells derived from 
n = 3 subjects). (d) RT-PCR analysis of AXIN2 expression following Wnt3a-treatment of human myogenic 
cultures, *P < 0.05; **P < 0.001; ns: non-significant (cells derived from n = 3 subjects). (e) qRT-PCR analysis of 
AXIN2 expression in human myogenic progenitors cultured in differentiating conditions for 48 h  with Wnt3a, 
Dkk-1 or a combination of both relative to proliferating control, P < 0.05 (cells derived from n = 3 subjects). 
(f) Immunocytochemistry of total-β-catenin expression in control and Wnt3a-treated cultures (4 days). (g) 
Immunofluorescent quantification of nuclear total-β-catenin in MHCPos myotubes in control and Wnt3a-treated 
cultures (4 days), scale bars = 100 µm. (h) Immunofluorescent quantification of nuclear total-β-catenin in 
unfused MHCNeg cells in control and Wnt3a-treated cultures (24 h). (i) Immunofluorescent quantification of 
mean myotube size in control Wnt3a or Dkk-1-treated myogenic cells (24 h). All bar charts are mean ± SD. For 
quantitation of immunofluorescence 6–10 independent fields of view were analysed per condition from n = 3 
representative myogenic cell populations.
www.nature.com/scientificreports/
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treated cultures confirmed comparable total-β-catenin and MHC expression (Fig. S1) despite a dose dependent 
reduction in active-β-catenin expression relative to control (Fig. S1). A TOP/FOP FLASH assay, which measures 
TCF transcriptional activity, was performed to ascertain the level of secreted canonical Wnt ligands in differen-
tiating myogenic cell conditioned media collected between day 2–3 of differentiation. In this reporter assay, the 
TOP-FLASH plasmid luciferase is driven by functional TCF binding sites whereas the FOP-FLASH plasmid has 
mutated, non-functional TCF binding sites and serves as a negative control. The TCF transcriptional activity is 
shown as a ratio of TOP-FLASH to FOP-FLASH luciferase-mediated signals. This assay detected secreted canon-
ical Wnts in all differentiating cultures obtained from different subjects, (n = 3) (Fig. S2).
These results suggest that while both Wnt3a and Dkk-1 modulate key components of this signalling pathway, 
neither factor alone is able to substantially effect myogenic differentiation. Whilst we were able to increase and 
decrease Wnt signalling via recombinant ligands acting at the level of cell surface receptors, it is wholly possible 
that the cells were able to constrain the strength of the Wnt signalling to within a homeostatic limit via the reg-
ulation of pathway components. Indeed, the increases in active-β-catenin protein when Wnt3a was added were 
modest and β-catenin remained readily detectable in the presence of Dkk-1.
Active GSK3β is required for the fusion and differentiation of human CD56Pos myogenic pro-
genitor cells. In order to overcome potential autoregulation of the Wnt-β-catenin pathway we sought to 
experimentally increase cystolic β-catenin in adult human myogenic progenitors via small molecule inhibition 
of GSK3β, a core component of the canonical Wnt pathway and an essential regulator of β-catenin stability. We 
studied the effects of the GSK3α/β inhibitor, BIO25, on the progression of myogenic differentiation at 24 hours 
and 4 days following serum withdrawal corresponding to our definition of early and late stages of differentiation, 
respectively. These time points were selected as they allowed us to study both the initial stages of myogenic pro-
genitor cell fusion and later their terminal differentiation into multinucleated myotubes.
In stark contrast to both control and Wnt3a-treated cultures, which showed evidence of fusion and myotube for-
mation at 24 hours under differentiating conditions, BIO-treated cultures showed very poor fusion with most cells 
remaining as mononucleated desminPos progenitors (Fig. 3a). Although BIO-treated cultures showed some evi-
dence of cell alignment (Fig. 3a), these cells exhibited a far less pronounced sequestration of total-β-catenin at the 
intracellular plasma membrane where β-catenin is known to play its crucial role in adherens junction formation8; 
instead cells cultured with BIO expressed total-β-catenin abundantly throughout the cytoplasm (Fig. 3b, Fig. S3).
In control cultures, after 24 hours in differentiation medium, nuclear accumulation of active-β-catenin could 
be observed within MHCPos cells (Fig. 3c, Fig. S4). However in BIO-treated cultures, myogenic fusion index was 
heavily depressed and quantification of nuclear fluorescence intensity revealed that these cells expressed more 
than twice the amount of nuclear active-β-catenin as measured in control conditions (Fig. 3c–e). Whilst myotube 
size was reduced in BIO-treated cultures (Fig. 3c and f; Fig. S4), the number of small MHChigh cells per field of 
view was significantly increased (Fig. 3g,h). Therefore taken together BIO-treated populations had increased 
expression of both total-and active-β-catenin, which led to an abundance of small MHCHigh myotubes, which had 
failed to achieve their full potential for myogenic fusion suggesting a deregulation of the myogenic regulatory 
program upon GSK3β inhibition.
GSK3β inhibition strongly inhibits the onset of myogenin expression under differentiating 
conditions. In control human myogenic populations cultured in differentiating conditions for 24 hours, sites 
of cell-to-cell contact showed a high level of total-β-catenin expression (Fig. 4a). In contrast, BIO-treated cells 
showed a far less robust accumulation of total-β-catenin at cell-cell contact sites, but cytoplasmic and nuclear 
levels were far higher than that observed in control conditions (Fig. 4a). To check whether this mislocalisation 
of total-β-catenin might impact upon the core transcription factor network governing myogenesis, we assessed 
the localisation and expression of myogenin, a key transcriptional regulator of myogenic differentiation26. This 
transcription factor could be clearly identified in the nuclei of differentiating human myogenic progenitors 
after 24 hours of serum withdrawal (Fig. 4b). However, consistent with the stunted myotube differentiation in 
BIO-treated cultures, myogenin expression was heavily suppressed in these cultures when compared to untreated 
control populations (Fig. 4c). Cell-by-cell analysis of myogenin immunofluorescent intensity further confirmed a 
large and highly significant reduction in nuclear myogenin levels under conditions of GSK inhibition (Fig. 4d). In 
contrast, early differentiation in the presence of Wnt3a did not significantly prevent the upregulation of myogenin 
and myotube formation was highly comparable to control populations (Fig. S2). Thus at this early time point of 
differentiation, these data suggest that additional stimulation of receptor mediated Wnt signalling does not abro-
gate myogenic differentiation, whereas small molecule disruption of GSK3β activity has a profoundly inhibitory 
impact on myogenin expression under differentiating conditions (Fig. 4b–d).
To see whether myogenic differentiation is simply delayed when GSK3β is constitutively inhibited, we main-
tained human myogenic cells until day four (late differentiation) with or without Wnt3a or BIO supplementa-
tion. By late differentiation, control populations differentiated into large, multinucleated myotubes and the nuclei 
within these MHCPos structures stained strongly for active-β-catenin (Fig. S3). Quantification of fusion index 
showed that while >70% of cells in both control and Wnt3a-treated cultures were incorporated into myotubes 
after four days <10% of myogenic cells had fused in BIO supplemented cultures (Fig. S3). This lack of fusion 
cannot be attributed to a loss of myogenic fate amongst CD56Pos derived progenitors as the unfused MHCNeg 
cells remained as desminPos mononuclear cells (Fig. S3); nor can it be attributed to differences in cell density as 
the total nuclear area per field of view between control and BIO cultures was not significantly different between 
the three culture conditions (data not shown). In line with the successful terminal myogenic differentiation in 
control and Wnt3a-supplemented cultures, all nuclei within myotubes ubiquitously expressed myogenin at day 
4 of differentiation (Fig. 4e,f). Contrastingly, there was a large reduction in myogenin expression in BIO-treated 
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Figure 3. Active GSK3β is required for the fusion and differentiation of human CD56Pos myogenic progenitor 
cells. (a) Representative micrographs of desminPos human myogenic cells 24 h after induction of differentiation in 
control, Wnt3a and BIO-treated cultures. (b) Immunocytochemistry of total-β-catenin expression in myogenic 
cells exposed to control, Wnt3a and BIO-supplemented differentiation media. (c) Representative micrographs 
of active-β-catenin and MHC immunostaining of control and BIO-treated human myogenic cells (24 h). (d) 
Immunofluorescent quantification of nuclear active-β-catenin in control and BIO-treated cultures (24 h). 
(e) Immunofluorescent quantification of myotube fusion index in control and BIO-treated cultures (24 h). 
(f) Immunofluorescent quantification of mean myotube area in control and BIO-treated cultures (24 h). (g) 
Immunofluorescent quantification of myotube MHC fluorescent intensity in control and BIO-treated cultures (24 h). 
(h) Immunofluorescent quantification of the mean number of myotubes per field of view in control and BIO-treated 
cultures. All bar charts are means ± SD. For quantitation of immunofluorescence 6–10 independent fields of view 
were analysed per condition from n = 3 myogenic cell populations, ***P < 0.001 compared to control. All scale 
bars = 100 µm.
www.nature.com/scientificreports/
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Figure 4. Myogenin expression is inhibited in human myogenic cells following GSKβ inhibition. (a) 
Representative micrographs of control myogenic cultures show clear accumulation of total-β-catenin 
(arrowheads) at the periphery of fusing myotubes while BIO-treated cultures display noticeably less junctional 
total-β-catenin staining (24 h). (b) Representative micrographs of myogenin expression in desminPos human 
myogenic cultures in differentiation media (24 h). (c) Representative micrographs of myogenin expression in 
desminPos human myogenic cultures after treatment with BIO for 24 h. (d) Quantification of nuclear myogenin 
fluorescent intensity in individual cells in control and BIO-treated myogenic cultures (24 h), ***P < 0.001; 
(e) Representative micrograph of myogenin expression in human myogenic cells differentiated for 4 days. (f) 
Representative micrograph of myogenin expression in myogenic cultures subjected to differentiation conditions 
in the presence of Wnt3a (4 days). (g) Representative micrograph of myogenin expression in myogenic cultures 
subjected to differentiation conditions in the presence of BIO (4 days). (h) Quantification of mean myotube area 
in control, BIO and Wnt3a-treated cultures. (i) Quantification of mean MHC fluorescent intensity in control, 
www.nature.com/scientificreports/
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populations (Fig. 4g; Fig. S5) along with a significant reduction in myotube area (Fig. 4h) and MHC immunoflu-
orescent intensity (Fig. 4i).
Notably, under control differentiation conditions there was almost no expression of myogenin in cells located 
outside myotubes (MHCNeg), which are comprised of myogenic cells that have failed to differentiate (including 
reserve cells) (Fig. 4j,k; Fig. S5). However, BIO supplemented cultures showed evidence of atypical myogenin 
and MHC expression (Fig. 4j,k; Fig. S5) as evidenced by a significant increase in myogeninPos/MHCNeg cells and 
to a greater extent MHCPos/myogeninNeg cells in BIO cultures (Fig. 4j,k; Fig. S5). In order to confirm that myo-
genin is directly modulated by BIO we allowed myogenic cultures to differentiate for 2 days so that they started 
to fuse, forming myogeninPos myotubes before applying BIO for a further 24 h. Only in BIO-treated cultures did 
we observe a significant reduction in myogenin expression, indicating a direct modulation of myogenin by BIO, 
independent of fusion (Fig.S5).
In order to assess whether BIO-mediated disruption of myogenin expression was due to myogenic cells being 
stalled in a proliferative state, we assayed the percentage of Ki67Pos cells in proliferation media (24 h), differentia-
tion media and differentiation media supplemented with BIO (72 h). Immunostaining revealed that as expected 
myogenic cells maintained in proliferation media were almost exclusively Ki67Pos/myogeninNeg while cells main-
tained in differentiation media contained a high percentage of myogeninPos cells and lacked discernible expression 
of Ki67 (Fig. S6). Interestingly, cultures treated with BIO had significantly more Ki67Pos cells and lacked notable 
myogenin expression. Therefore, BIO-mediated disruption of myogenin is accompanied by an increase in myo-
genic cells stalled in a proliferative state.
To test that the differentiation defects in BIO cultures were not a result of non-specific effects of the BIO 
compound itself, we performed the same experiments using meBIO, its kinase inactive form (Fig. S7). Myogenic 
cells cultured with meBIO differentiated to the same extent as control populations and expressed an identical 
level and localisation of active-β-catenin and myogenin (Fig. S7). To explore the specificity of the role of GSK3β 
in the disrupted myogenic differentiation we repeated the differentiation process with two further inhibitors of 
GSK3β, which are structurally diverse, CHIR and LiCl (Fig. S7 and S8). Treatment with both CHIR (Fig. S7) and 
LiCl (Fig. S8) stabilised β-catenin while concomitantly suppressing myogenin expression and stunting myotube 
formation.
Taken together these series of experiments demonstrate that the pharmacological inhibition of GSK3β mark-
edly impairs the fusion and differentiation of primary adult human muscle progenitor cells through the deregu-
lation of myogenin expression.
The β-catenin-TCF transcriptional partnership is essential for the fusion and differentiation 
CD56Pos human myogenic progenitors. To test whether the greatly increased levels of β-catenin in 
GSK3β inhibited cultures were directly responsible for the suppression of myogenin and lack of fusion, we trans-
duced purified CD56Pos human myogenic progenitors with a lentiviral expression construct to induce the overex-
pression of active-β-catenin (EβC) which cannot be targeted for degradation by GSK3-mediated phosphorylation. 
In addition, to examine the necessity of the transactional co-activator role of β-catenin in human myogenic cell 
differentiation we also transduced purified primary cell lines with a construct overexpressing a dominant neg-
ative form of TCF4 (EdTC). This dominant negative mutant form of TCF4 harbours an N-terminal deletion, 
such that it binds Wnt target genes, but cannot transactivate them due to its inability to bind β-catenin21,27. In 
both cases successful integration was identified by mCherry expression (Fig. 5a,b). Fluorescent microscopy was 
used to confirm a reproducible rate of transduction, which in all cases exceeded 92% of the population (Fig. 5b). 
Overexpression of active-β-catenin in EβC transduced cells was confirmed by both western blot and immunoflu-
orescence analysis (Fig. 5c). EdTC overexpression on the other hand, had little impact on β-catenin expression, 
which is consistent with its mechanism of action (Fig. 5c). Observation of EβC-treated cultures revealed a reduc-
tion in myogenic fusion, while EdTC cultures showed a much more severe failure of differentiation (Fig. 5d).
To assess whether β-catenin might exert a pro-differentiation effect, as has been suggested for mouse myo-
genic cells12, we cultured EβC-transduced cells in growth medium conditions. Interestingly, EβC significantly 
decreased the percentage of Ki67Pos actively proliferating cells, but in the absence of differentiating conditions did 
not drive myogenic differentiation confirmed by a lack of MHC expression in both EβC and control myogenic 
cells when cultured in growth media (Fig. 5e).
EβC overexpression in differentiating conditions resulted in easily identifiable increases in nuclear 
active-β-catenin and MHCPos myotubes were evidently thinner than their autologous control counterparts. 
Nuclear myogenin was also found to be reduced in EβC cultures (62% ± 8%) compared to control cultures 
(74% ± 4%) (Fig. 5f,g). In aggregate, this suggests that β-catenin alone is not sufficient to drive differentiation 
while increases above a pre-defined range can negatively affect differentiation. Interestingly EdTC-transduced 
cells had drastically reduced expression of active-β-catenin, were extremely thin, did not undergo fusion or dif-
ferentiation and did not express any detectable levels of myogenin or MHC protein (Fig. 5d and f,g), suggesting 
an active-β-catenin-TCF complex in human myogenic differentiation is essential.
To uncover the molecular mechanisms underpinning the phenotypes observed, we performed qRT-PCR anal-
ysis on transduced cells maintained in either proliferating or differentiating conditions. In Fig. 5h–k, each symbol 
BIO and Wnt3a-treated cultures. (j) Quantification of nuclear myogenin in MHCneg cells only in control, 
BIO and Wnt3a-treated cultures. (k) Quantification of myogeninPos/MHCNeg and myogeninNeg/MHCPos cells. 
All bar charts are means ± SD. In all cases *Indicates P < 0.05 compared to both control and Wnt3a-treated 
human myogenic cultures; analysis was performed on n = 4 independent myogenic cell populations. Scale 
bars = 100 µm.
www.nature.com/scientificreports/
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Figure 5. Lentiviral manipulation of Wnt-β-catenin signaling. (a) Schematic of the lentiviral constructs. 
(b) Representative micrographs of mock, EβC and EdTC-transduced cells, scale bar = 50 µm. (c) Western 
immunoblotting for active-β-catenin and total-β-catenin in mock, EβC and EdTC-transduced cells. (d) 
Representative micrographs of mock, EβC and EdTC-transduced human myogenic cultures after 4 days in 
differentiation media, scale bar = 200 µm. (e) Ki67/MHC immunostaining of mock and EβC human myogenic 
cells in proliferative conditions (24 h), scale bar = 100 µm. (f) Desmin/active-β-catenin immunostaining of 
mock, EβC and EdTC human myogenic cultures. (g) MHC/myogenin immunostaining of mock, EβC and 
EdTC human myogenic cultures (4 days), scale bar = 50 µm. (h–k) qRT-PCR analysis following of EβC/
EdTC myogenic cells cultured in either growth or differentiation media for 48 hours, each symbol represents 
individual cultures derived from different biopsies and shows gene expression relative to mock control from the 
same individual, (n = 3–5).
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represents a different individual and their subsequent readout for the corresponding gene. This analysis revealed 
that overexpression of β-catenin (EβC) reproducibly led to increased AXIN-2 expression relative to mock con-
trol, however, a variable response was noted depending on the individual, ranging from a moderate, 2–7 fold, 
increase to a very high, 17–19 fold, increase. EβC-transduced cells cultured in growth medium underwent active 
suppression of myogenic regulatory genes, with the exception of Myf5 (Fig. 5h). This supports the contention that 
canonical Wnt signalling alone does not induce differentiation in human myogenic cells in growth conditions 
(Fig. 5h). Analysis of EβC cultures in differentiation medium confirmed a moderate but variable upregulation 
of β-CATENIN and TCF (endogenous form), MYF5, MYOD, and MHC transcripts when compared to mock 
transduced controls (Fig. 5i). Quantitative RT-PCR analysis of TCF4 dominant negative (EdTC) cultures after 
48 hours in either proliferating or differentiating conditions all showed decreased expression of AXIN-2 along 
with significantly reduced levels of MYOGENIN and MHC transcripts relative to mock control (Fig. 5j,k). Taken 
together this shows that an optimal level of β-catenin is required for efficient human myogenic cell fusion and 
differentiation while an intact β-catenin-TCF complex is essential (Fig. 6).
Discussion
Wnt proteins and their signalling pathways have been the subject of intense investigation in recent years owing to 
their important roles in a vast array of developmental, homeostatic and disease processes28–32. Of the three main 
branches of Wnt signalling, the canonical pathway, which is dependent on β-catenin, is essential for the formation 
of skeletal muscle during embryogenesis4. Despite the necessity of this pathway for developmental myogenesis, 
there has been considerable controversy surrounding the actions of β-catenin in adult mouse muscle17,33–35, while 
its role in human muscle remains completely uncharacterised.
In the present work we manipulated the activity and/or level of three key nodes in the Wnt signalling pathway, 
GSK3β, β-catenin and TCF4/TCF7L2 in primary human myogenic progenitor cells6, in order to identify possible 
roles for this pathway in the regulation of myogenic differentiation. Our data revealed that manipulation of Wnt 
signalling outside of pre-defined limits were detrimental to human in vitro myogenesis. Throughout this process 
we revealed a previously unidentified necessity for active GSK3β in the fusion and efficient terminal differentia-
tion of human myoblasts via its regulation of myogenin.
The demonstration of abundant protein expression of both nuclear active and total forms of β-catenin in rest-
ing adult human skeletal muscle in situ indicates that the Wnt-β-catenin pathway is operational in vivo (Fig. 1). 
We next sought to examine a possible role for Wnt signalling in an in vitro model of regenerative myogenesis6,20. 
In purified populations of CD56Pos myogenic progenitor cells we demonstrated that the nuclear levels of 
active-β-catenin in proliferating progenitors were low. We define high nuclear accumulation as the point at which 
the nucleus of cells could be demarcated by positive beta-catenin staining alone, without the need to refer to 
Hoechst. However, after 24 hours of serum withdrawal, a trigger for myogenic differentiation, nuclear accumu-
lation of active-β-catenin became readily upregulated (Fig. 1). By four days of serum-free culture almost every 
nuclei within terminally differentiated MHCPos myotubes expressed clear nuclear staining of active-β-catenin 
(Fig. 1). This is contrary to observations made by Otto et al. who identified the regulation of proliferation as the 
primary role of nuclear active-β-catenin in mouse satellite cells30. Our data is, however, consistent with the work 
of Brack et al. who also showed a marked increase in canonical Wnt signalling at the onset of differentiation12.
Given the proposed roles of Wnt-β-catenin signalling in regulating myogenic differentiation we sought to 
activate the canonical Wnt pathway by treating purified populations of myogenic progenitors with soluble recom-
binant Wnt3a (Fig. 2). Similar to previous studies we utilised both the stabilisation of β-catenin protein and 
AXIN2 mRNA as readouts of active canonical Wnt signalling12,36 and confirmed a significant increase in active 
signalling following Wnt3a stimulation (Fig. 2a–e). We also showed that canonical pathway activation could be 
competitively inhibited using the Wnt signalling antagonist, Dkk-137 (Fig. 2e). However, to our surprise, despite 
clear modulation of the pathway, neither Wnt3a nor Dkk-1 conferred any substantial effect on the successful 
completion of myogenic differentiation (Fig. 2f–i; Supplementary Figures S2 and S3). We postulated that the 
addition of Wnt3a may potentially have been unable to activate the canonical pathway in a sustained manner, 
owing to the reported presence of negative feedback loops that serve to regulate the intensity and duration of 
the Wnt signal36,38. AXIN2, a direct Wnt target and negative regulator, is known to augment the GSK3β mediated 
phosphorylation of β-catenin by several thousand fold, greatly increasing β-catenin degradation39. Our data show 
strong induction of AXIN2 within 2 hours of Wnt3a administration supporting the activation of this negative 
feedback loop. In order to circumvent this issue we decided to stabilise β-catenin via pharmacological inhibition 
of GSK3β (GSKi) using three structurally diverse molecules (BIO, LiCL and CHIR40), all of which have been 
shown to activate canonical Wnt signalling in a variety of different systems. We confirmed the ability of these 
compounds to bypass AXIN-mediated negative feedback to stabilise the active form of β-catenin in our human 
myogenic progenitors (Fig. 3,4,  S7 and S8).
In contrast to the lack of phenotype observed with the addition of soluble Wnt3a, GSKi via either BIO, CHIR, 
or LiCL led to a severe blunting of the normal differentiation response with significant reductions in fusion index, 
individual myotube size and overall MHC expression in the treated cultures. The pronounced loss of differenti-
ation potential in GSKi cultures suggested a role for GSK3β activity in regulating MRFs, which are essential for 
skeletal myogenesis during embryonic development and for post-natal regenerative myogenesis41. Of the MRFs, 
myogenin is known to be critical for terminal differentiation26,42. Irrespective of the inhibitor used, we were able 
to show that GSKi was associated with a significant repression of myogenin (Fig. 4 and Fig. S7–S8). GSKi cul-
tures also had an increased number of cells with mutually exclusive expression of myogenin and MHC, which 
were only rarely observed in control populations (Fig. 4 and S5). BIO was also shown to modulate expression of 
myogenin independent of fusion (Fig. S5). Interestingly, cultures treated with BIO for 72 hours in serum-free dif-
ferentiation also had significantly more Ki67Pos cells indicating that the cells were either continuing to proliferate 
or were stalled as progenitors (Fig. S6). However, as the number of cells/field of view did not increase or decrease 
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Figure 6. Active GSK3β is an absolute requirement for the terminal differentiation of human myogenic 
progenitor cells. (a) Serum withdrawal stimulates myogenic cells to align, fuse and differentiate to form 
multinucleated myotubes. After 24 h active-β-catenin expression had become localised to the nucleus of 
myogenic cells, which had begun to align/fuse. Continued mitogen withdrawal for 4 days resulted in the 
formation of terminally differentiated myotubes, which were multinucleated and expressed the terminal 
differentiation markers myogenin and MHC. (b) Graphical illustration shows the key nodes of the Wnt 
pathway that were perturbed. (c) Treatment of myogenic populations with GSK3β inhibitors markedly 
reduced myogenic cell fusion, myotube formation and myogenin expression compared to control and Wnt3a 
supplemented cultures. (d) Genetic manipulation with lentiviral vectors to overexpress active-β-catenin 
(EβC) or dominant negative TCF4 (EdTC) similarly reduced the capacity of human myogenic cells to undergo 
myogenic differentiation. EβC had marked effects on the completion of myogenic differentiation while EdTC 
lead to a robust inhibition of myogenic differentiation thus uncovering a crucial role for this core canonical Wnt 
signalling transcription factor in the regulation of human myogenic differentiation.
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over the culture period when compared to control populations, and there was no indication of increased cell 
death (Fig. S6), it appears that these cells were unable to progress beyond the progenitor phase.
This suggests that GSKi leads to a dysregulation in the typically co-ordinated sequence of MRF expression 
leading to failures in fusion and differentiation. Use of three structurally diverse inhibitors of GSK3β suggested 
that the phenotypes observed were based on loss of GSK3β activity as opposed to off target effects43. Furthermore, 
the observation of normal differentiation using meBIO, an almost structurally identical molecule to BIO, but 
lacking its ability to inhibit GSK3β44,45, ruled out the possibility of non-specific toxicity.
That GSKi and Wnt3a did not produce the same outcome for myogenic differentiation is perhaps surprising 
given that GSK3β inhibitors are often used as a proxy for canonical Wnts. At least some of this discrepancy may 
be attributable to the different mechanisms of action of the GSK3β inhibitors and Wnt proteins46. Inhibitors of 
GSK3β reduce the catalytic activity of GSK3β, which allows β-catenin to escape degradation. In comparison, the 
prevailing view is that binding of Wnts to their cell surface receptors does not affect the kinase activity of GSK3β, 
but rather blocks the destruction complex by sequestering it at the cytoplasmic tail of LRP at the cell membrane46. 
In comparison the reduced accumulation of β-catenin observed at cell-cell contact sites in GSKi conditions may 
have contributed to lower fusion47. Disruption of cell-cell cadherin ligation is known to abrogate myogenic cell 
fusion48 and previous authors have suggested a mechanism by which reductions in GSK-mediated cadherin phos-
phorylation can reduce its affinity for β-catenin49,50.
To ascertain whether the differentiation phenotype we observed was due solely to increased β-catenin expres-
sion and to overcome any concerns over the specificity of inhibitors of GSK3β, given the role of this kinase 
beyond canonical Wnt signalling, we used a highly efficient lentiviral-overexpression constructs containing an 
active form of β-catenin (EβC). Overexpression of active-β-catenin produced a phenotype of reduced fusion and 
myotube size, which was similar but less severe than that observed with GSKi (Fig. 5). This was likely due to main-
tained expression of myogenin in the case of EβC (Fig. 5), but not in GSKi conditions (Fig. 4). In turn this suggests 
that active GSK3β is required for the induction of myogenin independently of β-catenin.
Given that β-catenin is highly upregulated during normal myogenic differentiation we sought to determine 
whether β-catenin overexpression in proliferation conditions may stimulate myogenic differentiation. Rather this 
led to a moderate downregulation in MRFs (Fig. 5h) and did not stimulate myotube formation (Fig. 5e). In sup-
port of our data, Goichberg et al., also observed a reduction in myogenin following β-catenin overexpression from 
a retroviral vector in growth medium8. We did however uncover a reduction in the proportion of proliferating 
progenitors with EβC overexpression (Fig. 5e). Conversely, when conditions were permissive for differentiation, 
β-catenin overexpression led to moderate increases in expression of MRFs and MHC in two of the three individ-
uals tested. Nonetheless, the myotubes that formed in EβC cultures were noticeably thinner and more numerous 
per field of view than control myotubes. Thus, in primary human myogenic cells it appears that β-catenin alone is 
not sufficient to drive differentiation in non-permissive conditions and that it likely interacts with other factors, 
which are dependent on the cellular context.
To examine the co-activator role of β-catenin in myogenic differentiation we overexpressed a dominant-negative 
mutant form of TCF4 (EdTC). EdTC is able to bind DNA at Wnt target genes, but cannot transactivate them due 
to its inability to bind β-catenin51. Schuijers et al.27 demonstrated that overexpression of dnTCF4 was sufficient to 
abolish almost all β-catenin/DNA interaction, elegantly confirming that canonical Wnt signalling is exclusively 
transduced via TCF transcription factors27. In our hands knockdown of TCF-driven transactivation severely 
disrupted differentiation (Fig. 5). In EdTC cultures, levels of all myogenic regulatory factors were significantly 
downregulated in both proliferation and differentiation conditions (Fig. 5). Furthermore, myogenin and MHC 
were greatly diminished at the protein level (Fig. 5g). Thus, we show here that β-catenin-TCF interactions are 
indispensable for human myogenic differentiation. As the same phenotype was observed across multiple separate 
transductions of primary cells from different human participants this strongly suggests that the findings were not 
attributable to disruptive positional effects of the construct integration. In line with our work, previous studies in 
mice have suggested that TCF4 might directly regulate MHC expression by direct interaction with the promoter/
enhancer region of MHC genes52–55.
Recent work in mice whereby either the Wnt agonist BIO was administered or β-catenin was overexpressed 
specifically in satellite cells following muscle injury, demonstrate a striking phenotype of vastly protracted regen-
eration and the appearance of many small fibres56. This was also seen in vivo with β-catenin overexpression in 
mouse muscle34. Another study, which knocked out APC in mouse satellite cells leading to unrestrained β-catenin 
activation produced similar findings57. Recently, Rudolf et al. showed that loss of beta-catenin lead to protracted 
and incomplete regeneration but that over-expression of increased active beta-catenin resulted in precocious dif-
ferentiation in mouse myogenic cells. These authors argued that both increased or loss of Wnt-β-catenin signal-
ling leads to impaired in vivo muscle regeneration with decreases in satellite cell self-renewal, decreased fibre size 
and excess collagen deposition10. Collectively, these studies and ours suggest that the manipulation of β-catenin 
above or dramatically below physiological levels is broadly disruptive to myogenesis. In contrast, Murphy et al. 
utilised a Pax7-Cre driver and did not observe any phenotype from loss of β-catenin suggesting that it is dispen-
sable for regenerative myogenesis in the adult34. However, because Cre-based recombination is imperfect, not all 
satellite cells will have deleted the gene entirely. In addition satellite cells are abundant in muscle with estimates 
of 5–7 per fibre; once activated they are highly proliferative and only a few cells are needed to regenerate and 
repopulate a large area of muscle58. If a knockout and wild type cell were able to fuse, β-catenin from the wild type 
cell could be shared rendering the knockout obsolete. Thus a very small number of ‘escaper cells’ with functional 
β-catenin could potentially compensate. As the level and localisation of β-catenin in this study was not quantified 
over time, the extent of β-catenin expression following the experimental manipulations remains unclear34.
We have demonstrated that canonical Wnt signalling is present in adult human skeletal muscle in situ and 
active in CD56Pos myogenic progenitors in vitro. The present study provides evidence that β-catenin is dynami-
cally regulated during the different phases of myogenesis increasing as differentiation progresses. Manipulation 
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of key Wnt signalling components during differentiation has unique outcomes. GSKi leads to inhibition of myo-
genesis whilst Wnt proteins, which activate the signalling pathway (Fig. 2), have little effect; these data bring into 
question the use of GSKi as a proxy for Wnt signalling. Despite its onset in our in vitro differentiation paradigm, 
further increases in the amount of active-β-catenin in growth conditions does not promote differentiation, but 
rather inhibits it. This is evidenced by a trend towards lower expression of genes associated with myogenic dif-
ferentiation and no increase in MHC or myogenin as detected by immunostaining (Fig. 5). On the other hand, 
during differentiation, myogenic genes tended to increase with β-catenin overexpression but this did not trans-
late into better myotube formation; in fact, myotubes were very clearly thinner with an increased background 
of unfused cells (Fig. 5). Thus, our work demonstrates that β-catenin can exert opposing effects on myogenesis 
depending on whether cells are exposed to conditions, which favour proliferation or differentiation. In the knowl-
edge that differentiation fails with the addition of dominant negative TCF it appears that, for optimal myogenic 
differentiation, a specific level of Wnt signalling is critical. An appreciation of how core components in the canon-
ical Wnt pathway influences the progression of adult myogenesis may assist us in experimentally manipulating 
this pathway for therapeutic gain in conditions where muscle regeneration is compromised.
Methods
Cell isolation and culture. All studies were performed with UK National Health Service Ethics Committee 
approval and in accordance with the Human Tissue Act and Declaration of Helsinki. Using the Bergström needle 
biopsy technique59 with additional suction, muscle samples were obtained from the vastus lateralis of healthy 
young adult male volunteers (age 25.6 ± 3.5 years, height 179.0 ± 5.3 cm, weight 70.3 ± 8.6 kg) who gave written 
informed consent to participate in this study (n = 22). Muscle-derived cells were isolated, cultured for 5–7 days to 
expand numbers and immunomagnetically purified using anti-CD56 microbeads as described previously6,20. In 
all studies reported here primary human muscle-derived cells at passage 1 or 2 were used and at least 2–3 replicate 
wells were plated and analysed per condition.
After CD56Pos purification, cells were plated on collagen-coated (0.5 mg/ml calf skin collagen, Sigma, USA) 
borosilicate glass coverslips (Ø 13 mm; no. 1 thickness, VWR, UK) in 24 well plates (ThermoScientific, Germany). 
For western blotting and qRT-PCR experiments, cells were plated at 40,000 cells/35 mm dish. For proliferation 
cells were plated at 10,000 cells/well in 24 well plates and for differentiation cells were plated at 25–50,000 cells/
well. For all studies investigating differentiation the cell monolayer was rinsed three times with PBS prior to the 
switch from proliferation to differentiation medium to remove all traces of serum containing medium60. Full 
details of media conditions as described previously6.
Snap freezing of human skeletal muscle. To characterize the expression of CD56 and β-catenin in situ, 
human skeletal muscle biopsies obtained from healthy individuals were snap frozen in dry ice-cooled isopentane 
and cryosectioned at 10 μm thickness (n = 2). Tissue sections were stained as detailed below.
Pharmacological manipulation of Wnt-β-catenin signalling. 6-bromoindirubin-3′-oxime (BIO) or 
its kinase inactive form 6-Bromo-1-methylindirubin-3′-oxime (meBIO) (Merck Chemicals, UK) were diluted 
to a final working concentration of 5 μM46,61, lithium chloride (LiCl) (Sigma, UK) was diluted to a final working 
concentration of 20 mM/L, CHIR99021(CHIR) (Stemgent, USA) was diluted to a final working concentration of 
5 μM. Each was administered to cells at their working concentrations in an appropriate volume of serum-free dif-
ferentiation medium. In all cases the final concentration of DMSO was <0.2% v/v. Recombinant proteins Wnt3a 
and Dkk-1 (R&D Systems Europe Ltd., UK) were reconstituted in sterile PBS containing 0.2% BSA. Proteins were 
administered at 200–400 mg/ml (Wnt3a) and 600–1000ng/ml (Dkk-1) in serum-free skeletal muscle differentia-
tion medium containing 0.3% (w/v) BSA as a carrier protein.
TOP/FOPflash Assay. Dual Luciferase assay kit (Promega) based on TOPflash/FOPflash reporter plasmid 
system was used for the detection of β-catenin driven Wnt-transcriptional activity. The TOP Flash reporter con-
struct contains three optimal copies of TCF/LEF sites upstream of a thymidine kinase minimal promoter that, 
when bound by β -catenin induces transcription of luciferase reporter gene. FOP Flash contains mutated copies 
of the TCF/LEF that cannot be activated by β -catenin and was used as negative control. Luciferase reporter gene 
analysis was performed using the SaOS cell line treated with either control unconditioned media or media condi-
tioned by differentiating myogenic cells for 24 h. One day before transfection, 1 × 104 cells/well were seeded per 
well into a 24-well plate. After overnight incubation, the cells (90% confluence) were transiently co-transfected 
with 0.4 mg DNA of reporter constructs (TOP/FOP Flash) and control plasmid (pCMV-GLuc) using 1 mL 
Lipofectamine 2000TM (Invitrogen) in 50 mL OptiMEM I reduced serum media (Invitrogen, UK). Thereafter, 
the test cells were stimulated with control unconditioned media or conditioned media for 24 hours. Cells from 
the treated and control conditions were collected for dual luciferase assay (Firefly luciferase reporters and Renilla 
luciferase as internal control) according to manufacturer’s instructions. Each assay was performed in triplicate 
and the reporter activity expressed as mean ± SD.
Lentiviral transduction. To generate lentiviral supernatants, HEK293T cells were cultured overnight in 
dishes pre-coated with 0.1 mg/ml collagen solution (Sigma, UK) in DMEM, 10% FCS, 2% glutamax and 1% 
pen/strep until 70% confluent. A solution containing 6.5 µg pCMV Δ8.9 packaging plasmid, 3.5 µg VSV-g enve-
lope plasmid and 10 µg target construct were diluted in OptiMEM-1, combined with 30 µl Lipofectamine 2000 
(LifeTechnologies, UK) and incubated at room temperature for 20 min to allow complexes to form. The plasmid/
lipofectamine mixture was added dropwise to the HEK293 cells and incubated at 37 °C for 4 h before an equal 
volume of OptiMEM-1 was added. The lentiviral supernatant was collected 48 h post-transfection and concen-
trated using a lenti-X-concentrator kit (Clontech, USA) according to manufacturer’s specification and viral titre 
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measured using GoStix (Clontech, USA). The pseudovirus was stored at −80 °C until ready to use. Fresh primary 
human muscle-derived cells at passage 1 were seeded in 6 or 24-well plates and maintained at 37 °C for 24 h in 
growth media prior to transduction. Human myogenic cells were transduced at a supernatant to media ratio 
ranging from 1:15 to 1:40 with 8 µg/ml polybrene (Sigma, UK) in growth media devoid of antibiotics. A mock 
control, consisting of the same transduction mixture without the addition of lentivirus was performed for each 
subject. The infected target cells were monitored for mCherry expression using fluorescent microscopy and after 
48 h media was changed to growth media or differentiation media. In both cases the mouse ORF for β-catenin 
and TCF4/were expressed as β-catenin (central ARM domains) binding domains are 100% conserved between 
humans and mice. Primers were designed, which allowed us to measure endogenous transcripts to study activity 
at the host locus.
Immunocytochemistry. Cryosections and cultured cells were fixed by the addition of 4% paraformalde-
hyde in ice-cold PBS for 10 minutes. Cells were permeabilised after fixation by addition of 0.2% Triton-X100 
in PBS with 1% BSA and NaN3 (0.01%) for 10 minutes, then blocked and incubated with primary antibodies. 
This was followed by incubation with species-specific fluorescently-labelled secondary antibodies, and 10 minute 
incubation in Hoechst 33342 dye. Stained tissue sections and cells were mounted using ‘anti-fade gold’ medium 
(DAKO USA). Details of all antibodies used are shown in Supplementary Table 1.
Image analysis. Immunofluorescent probes were illuminated by epifluorescence and signals were visualised 
through red (filter set 45 HQ Texas red shift free), green (filter set 44 FITC special shift free) and blue (filter set 49 
DAPI shift free) band pass filters (Zeiss) on an AxioPlan microscope (Carl Zeiss; 10X, 20X, 40X, objectives with 
0.25, 0.75, 0.95 numerical apertures respectively). Greyscale images were captured using an AxioCam MRm digi-
tal camera (Zeiss). To measure the expression of myogenic transcription factors and transcriptional co-activators 
in individual nuclei, image analysis was performed using techniques described in Agley et al.6. For all analysis 
6–10 independent fields of view were analysed from two separate coverslips on cells derived from at least three 
representative myogenic cell populations. Only raw, greyscale images were used for quantitative analysis. Local 
background intensity values were subtracted from measurements to account for potential field to field variation 
in non-specific background fluorescence62.
Western immunoblotting. Cell lysates were prepared using ice cold lysis buffer containing phosphatase 
and protease inhibitors (Roche, UK). Protein content of the samples was quantified using the Bradford assay 
(Bio-Rad, UK). Protein samples to be analysed were mixed at a 1:1 ratio with 2x Laemmli sample buffer and dena-
turing discontinuous SDS-PAGE was performed using 4% and 10% acrylamide: bis-acrylamide (37.5:1) stack-
ing and resolving gels respectively. After SDS-PAGE had been performed, electro-blotting was performed using 
standard methods. Immobilised proteins were then probed overnight with primary antibodies. After washing, 
blots were incubated with the appropriate species-specific horseradish peroxidase (HRP)-conjugated secondary 
antibody (1:2000 dilution) for one hour at room temperature. Immuno-labelled protein bands were then visual-
ised using ECL Plus Western Blotting Detection Reagents (Amersham Biosciences, UK) and ECL Hyperfilm 
(Amersham Biosciences, UK). Band density was quantified using Scion Image analysis software (Scion Image, 
release Alpha 4.0.3.2, USA). β-tubulin or GAPDH expression were used for the normalisation of protein loading. 
Details of all antibodies used are shown in Supplementary Table 1.
Quantitative real-time polymerase chain reactions (qRT-PCR). Cell monolayers were rinsed with 
PBS and cells lysed directly in their culture dishes by the addition of TRIzol reagent (Invitrogen, UK). Isolation of 
RNA from TRIzol was performed as per the manufacturer’s instructions. RNA was reverse transcribed using the 
QuantiTect Reverse Transcription kit (Qiagen, UK) and RotorGene 6000 (Qiagen, UK) qPCR machine following 
the manufacturer’s instructions. qPCR was performed as described by Bailey et al.63 and normalised to 4 stable 
reference genes or as performed by Lewis et al.64. Primer sequences can be found in Supplementary Table 2.
Statistics. For experiments comparing only two groups, data were compared by unpaired t-test with Welch’s 
correction, which does not assume equal variances between groups; where data did not satisfy all parametric 
assumptions Mann-Whitney U tests were used to compare differences between groups. For all experiments com-
paring more than two groups a one or two way (if repeated measures or time as a factor) analysis of variance 
(ANOVA) was performed and specific time points were analysed via post-hoc Bonferroni’s multiple comparison 
test. In all cases n numbers are given for specific experiments and an alpha value of P < 0.05 was accepted as 
statistically significant. For quantification of immunofluorescent staining 6–10 independent fields of view were 
analysed per condition (pooled from two separate coverslips) on cells derived from at least 2–3 representative 
myogenic populations per experiment. In all other cases n numbers are given for specific experiments and an 
alpha value of P < 0.05 was accepted as statistically significant.
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